Seyed Jafari, S. Morteza; Feldmeyer, Laurence; Bossart, Simon; Simon, Dagmar; Schlapbach, Christoph; Borradori, Luca (2021). Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid. Frontiers in immunology, 11, p. 611549. Frontiers Research Foundation 10.3389/fimmu.2020.611549
|
Text
fimmu-11-611549.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (736kB) | Preview |
Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology |
UniBE Contributor: |
Jafari, Morteza, Feldmeyer, Laurence, Bossart, Simon, Simon, Dagmar, Schlapbach, Christoph, Borradori, Luca |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1664-3224 |
Publisher: |
Frontiers Research Foundation |
Language: |
English |
Submitter: |
Andrea Studer-Gauch |
Date Deposited: |
04 Jan 2022 15:34 |
Last Modified: |
02 Mar 2023 23:35 |
Publisher DOI: |
10.3389/fimmu.2020.611549 |
PubMed ID: |
33584689 |
Uncontrolled Keywords: |
bullous pemphigoid dupilumab omalizumab recalcitrant treatment |
BORIS DOI: |
10.48350/162120 |
URI: |
https://boris.unibe.ch/id/eprint/162120 |
Actions (login required)
 |
Edit item |